ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,277.51
      0.80%
      US Tech 100
      18,064.80
      0.02%
      Dow Jones
      38,686.32
      1.51%
      Brent Oil
      81.295
      0.00%
      Bitcoin
      67,700.34
      0.32%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Mustang Bio Inc (MBIO)

      7. Mustang Bio Inc (MBIO) News

      MBIO

      Mustang Bio (MBIO)

      Mustang Bio Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:MBIO
      DateTimeSourceHeadlineSymbolCompany
      05/31/20245:09PMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:MBIOMustang Bio Inc
      05/21/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
      05/13/20246:01AMEdgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:MBIOMustang Bio Inc
      05/02/20244:01PMGlobeNewswire Inc.Mustang Bio Announces Closing of $4 Million Public OfferingNASDAQ:MBIOMustang Bio Inc
      04/29/20248:00PMGlobeNewswire Inc.Mustang Bio Announces Pricing of $4 Million Public OfferingNASDAQ:MBIOMustang Bio Inc
      03/28/20249:00AMGlobeNewswire Inc.Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune DiseasesNASDAQ:MBIOMustang Bio Inc
      03/11/20244:30PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
      03/11/20244:05PMGlobeNewswire Inc.Mustang Bio Reports Full-Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
      03/11/20244:02PMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:MBIOMustang Bio Inc
      03/07/20247:30AMGlobeNewswire Inc.Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade GliomaNASDAQ:MBIOMustang Bio Inc
      02/14/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
      01/25/20244:07PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
      01/11/20248:30AMGlobeNewswire Inc.Mustang Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:MBIOMustang Bio Inc
      01/04/20244:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
      12/19/20234:06PMEdgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MBIOMustang Bio Inc
      12/11/20239:52PMEdgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MBIOMustang Bio Inc
      12/11/20238:37AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
      12/11/20238:30AMGlobeNewswire Inc.Mustang Bio Presents Updated Phase 1/2 Multicenter Clinical Data for MB-106 at the 2023 American Society of Hematology (ASH) Annual MeetingNASDAQ:MBIOMustang Bio Inc
      11/14/20234:44PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
      11/14/20234:05PMGlobeNewswire Inc.Mustang Bio Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:MBIOMustang Bio Inc
      11/03/20233:22PMEdgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:MBIOMustang Bio Inc
      11/02/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
      11/02/20239:28AMGlobeNewswire Inc.Mustang Bio Announces MB-106 CD20-Targeted CAR-T Data Selected for Presentation at 65th American Society of Hematology (ASH) Annual MeetingNASDAQ:MBIOMustang Bio Inc
      10/30/20232:57PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
      10/30/20232:15PMGlobeNewswire Inc.Mustang Bio Announces Closing of $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
      10/30/202310:30AMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:MBIOMustang Bio Inc
      10/26/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
      10/26/202312:30PMGlobeNewswire Inc.Mustang Bio Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesNASDAQ:MBIOMustang Bio Inc
      10/26/20239:00AMGlobeNewswire Inc.Mustang Bio Announces FDA Acceptance of IND Application for MB-109, a Novel Combination of MB-101 (IL13Rα2‐targeted CAR-T cell therapy) and MB-108 (HSV-1 oncolytic virus), for the Treatment of Recurrent Glioblastoma and High-Grade AstrocytomaNASDAQ:MBIOMustang Bio Inc
      10/04/20234:05PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBIOMustang Bio Inc
       Showing the most relevant articles for your search:NASDAQ:MBIO